Abstract. Photoacoustic (PA) imaging is an emerging medical imaging modality that combines optical excitation and ultrasound detection. Because ultrasound scatters much less than light in biological tissues, PA generates high-resolution images at centimeters depth. In recent years, wavelengths in the second near-infrared (NIR-II) window (1000 to 1700 nm) have been increasingly explored due to its potential for preclinical and clinical applications. In contrast to the conventional PA imaging in the visible (400 to 700 nm) and the first NIR-I (700 to 1000 nm) window, PA imaging in the NIR-II window offers numerous advantages, including high spatial resolution, deeper penetration depth, reduced optical absorption, and tissue scattering. Moreover, the second window allows a fivefold higher light excitation energy density compared to the visible window for enhancing the imaging depth significantly. We highlight the importance of the second window for PA imaging and discuss the various NIR-II PA imaging systems and contrast agents with strong absorption in the NIR-II spectral region. Numerous applications of NIR-II PA imaging, including whole-body animal imaging and human imaging, are also discussed. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI.
Introduction
In biomedical imaging, there is a huge demand for a noninvasive imaging modality that can provide high spatiotemporal resolution, high penetration depth, and anatomical and functional contrasts at an affordable price. Imaging modalities such as magnetic resonance imaging (MRI), x-ray computed tomography (CT), single-photon emission tomography (SPET), positron emission tomography (PET), and ultrasound (US) imaging, have been widely used for clinical and preclinical imaging. [1] [2] [3] [4] [5] Although they provide deeper penetration, leading to wholebody imaging, they have their own drawbacks. High-resolution MRI systems are expensive and slow for dynamic imaging. 6, 7 The x-ray CT and PET/SPECT use ionizing radiation and hence may not be suitable for frequent imaging. 8 US imaging cannot measure functional (physiological) changes, including metabolism, chemical composition, and absorption. 9 Optical imaging modalities, including fluorescence, multiphoton fluorescence, bioluminescence, optical projection tomography, optical coherence tomography (OCT), and diffuse optical tomography (DOT), were demonstrated for in vivo animal imaging. [10] [11] [12] These methods used nonionizing radiation, unlike CT scan (x-ray), SPET, and PET (gamma rays), and can provide structural as well as functional information at high resolution. [13] [14] [15] [16] However, due to the strong optical absorption and scattering of tissue, the imaging depth was limited to ∼0.1 mm (roughly the mean free path) in conventional widefield optical microscopy. 17, 18 OCT, on the other hand, used ballistic and quasi-ballistic photons for imaging and can image up to the transport mean free path (∼1 mm in biological tissue). It is currently in use for skin and eye imaging applications with an imaging depth of up to 2 mm. 19, 20 DOT offered several centimeters imaging depth by using diffused photons, but their image resolution was poor (approximately one-third of the depth) due to the multiple scattering the photons undergo. 21, 22 Recently DOT was used for monitoring neoadjuvant chemotherapy in patients with breast cancer. 23 Therefore, using pure optical imaging and achieving high spatial resolution at centimeters depth was a challenging task, until photoacoustic imaging (PAI) was explored.
PAI is a hybrid imaging modality rapidly moving from bench to bedside. 17, [24] [25] [26] [27] In PAI, a nanosecond-pulsed laser irradiates the tissue. On absorption of the pulsed light by the biomolecules (melanin, collagen, lipid, hemoglobin, myoglobin, bilirubin, cytochromes, water, DNA, RNA, etc.), it undergoes a time-varying thermal expansion-relaxation process, which leads to the generation of acoustic waves (known as PA waves) in the tissue. By acquiring the generated PA waves at the tissue surface and using various reconstruction algorithms, [28] [29] [30] [31] [32] [33] [34] [35] the absorption maps within the tissue can be obtained. By combining optical contrast and US resolution, PAI offers several advantages: (i) it is noninvasive and uses nonionizing radiation, hence it can be repeatedly used in vivo by keeping the excitation energy below the safety limit; (ii) it provides label-free imaging; (iii) it is speckle-free; (iv) it has higher penetration depth, up to ∼4 cm in vivo 36 and ∼12 cm in vitro; 37 (v) it is faster and less expensive compared to MRI, PET, x-ray CT; 38 (vi) it provides multiscale imaging, allows imaging organelles to organs with consistent contrast while keeping the same depth-toresolution ratio; 38, 39 (vii) it provides direct imaging of optical absorption with 100% relative sensitivity-the sensitivity of PAI is 100 times higher than that of OCT and confocal microscopy; and (viii) it provides anatomical, functional, molecular, and kinetic information. 40 PAI was successfully implemented as photoacoustic nanoscopy, [41] [42] [43] [44] [45] [46] photoacoustic microscopy (PAM), [47] [48] [49] [50] [51] [52] photoacoustic endoscopy, [53] [54] [55] [56] preclinical photoacoustic computed tomography/photoacoustic tomography (PACT/PAT), [57] [58] [59] [60] [61] [62] and clinical PACT. [63] [64] [65] [66] [67] [68] For deep-tissue imaging, PACT/PAT systems are suitable and hence hold better chance to find preclinical/clinical applications.
In the early days of PAT, green light (∼532 nm) was used due to the strong absorption of blood (an intrinsic contrast agent) in the visible region. 69 Label-free in vivo PAI of cell nuclei was performed in ultraviolet region (200 to 400 nm). 70 Two major components of cell nuclei, DNA and RNA, strongly absorb UV light at wavelengths around 260 nm. 71 However, due to the overwhelming scattering effect of tissues at shorter wavelengths (200 to 700 nm), the intensity of light and hence the PA amplitude exponentially decreases with depth with a decay constant of a few millimeters. 72 Later, PAI was performed in the near-infrared (NIR) region from 700 to 2500 nm, 73 where the tissue attenuation is low. The first NIR window (NIR-I) from 700 to 1000 nm was extensively investigated for deep-tissue imaging. [74] [75] [76] [77] Owing to the reduced blood absorption in this region, the penetration depth was improved with a small sacrifice in contrast. Several contrast agents based on metallic, inorganic (carbon nanotubes, quantum dots), organic small molecules (Indocyanine green-ICG, IRDye800, methylene blue), and semiconducting nanoparticles were developed for the NIR-I window, not only to enhance the contrast but also for targeted molecular imaging, drug delivery, therapy, etc. [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] Along with nanoparticles, reporter genes (RGs) were also used as PA agents in the range 400-800 nm. 89 To the best of our knowledge, RGs were not demonstrated for PAI beyond 1000 nm. There were few drawbacks associated with PAI in NIR-I window. To produce laser light in the NIR-I range, a pump laser (typically Nd:YAG) and a second stage, Ti:Shappire, dye laser, or OPO was required. This had made the laser system expensive, bulky, and very inefficient (20% to 30% efficiency is the best we can achieve in terms of the final laser output). Recently, pulsed laser diodes 57, [90] [91] [92] [93] [94] and light-emitting diodes 95-100 were reported as alternative sources for PAT in the NIR-I window; however, they provide low-energy pulses compared to traditional lasers (few mJ per pulse versus hundreds of mJ) and hence were not ideal for deep-tissue imaging. Another drawback of NIR-I window imaging was the low maximum permissible exposure (MPE), which was directly related to the penetration depth. For example, MPE at 800 nm is ∼300 mW∕cm 2 and MPE at 1064 nm is ∼1000 mW∕cm 2 per pulse according to American National Standards Institute (ANSI) safety limit. 101 Recent studies on optical imaging have found a new biological window, termed as the second NIR window (NIR-II) from 1000 to 1700 nm. [102] [103] [104] [105] [106] [107] [108] Second window has numerous merits, including (i) more MPE, i.e., more energy can be deposited on the tissue for imaging; this results in deeper light transmission inside tissue with longer wavelength excitation, (ii) reduced tissue scattering, thus making the tissues more transparent at longer wavelengths, (iii) minimal autofluorescence, reduces the background signal in fluorescence imaging, and (iv) maximized oxyhemoglobin absorption around 1064 nm, thus allowing the measurement of tissue oxygenation levels deep inside the tissue. 109 Unfortunately, water (one of the major endogenous chromophore) exhibits strong absorption in the range from 1400 to 1500 nm 106 and hence this range of wavelengths may not be ideal for optical as well as photoacoustic deep-tissue imaging. Hence, the shorter wavelengths within the NIR-II window (1000 to 1400 nm) are explored for PAI applications. [110] [111] [112] [113] [114] [115] The PA signal generated by NIR-II wavelengths is weak and hence effective contrast agents are often necessary for enhancing the image contrast. With the increasing demonstrations on the advantages of PAI, efforts are made to develop strong NIR-II absorbing organic, 37, [116] [117] [118] inorganic, [119] [120] [121] [122] [123] [124] [125] [126] etc. Although, these nanoparticles show broad absorption spectrum in the NIR-II window, most of them are demonstrated for PAI at 1064-nm wavelength because 1064-nm nanosecond laser (Nd:YAG laser) is commercially available.
In this review, we focus on the NIR-II PAI systems, contrast agents, and their preclinical and clinical applications. The review is organized in the following order: Sec. 2 discusses the motivation for NIR-II PAI, Sec. 3 discusses about in vitro imaging, Sec. 4 discusses about in vivo small animal imaging, Sec. 5 is dedicated to in vivo human imaging, Sec. 6 discusses about high-resolution imaging in the second window, Sec. 7 presents the summary and perspectives, and in Sec. 8, we conclude the review.
Motivation for Near-Infrared-II Photoacoustic Imaging
Typical processes that are involved in light-tissue interactions when a laser beam penetrates through biological tissues are reflection, autofluorescence, scattering, and absorption. 127 In photoacoustics, the imaging depth is majorly governed by absorption and scattering coefficients of the tissue. The absorption coefficients are strongly affected by the presence of blood, particularly at wavelengths below 600 nm (in the visible region). Figure 1(a) shows the absorption coefficients of tissue chromophores, including oxyhemoglobin (HbO 2 ), deoxyhemoglobin (Hb), lipid, and water in the range from 200 to 1400 nm. From this graph, it is clear that in the NIR region the blood absorption is low, and hence the penetration depth is majorly decided by the scattering of light and absorption of water in biological tissues. A study on human brain tissue found that the region from 1000 to 1100 nm can provide better penetration depths for brain tissues. The results have proven that in the 1000-to 1100-nm region the scattering coefficients reduce with wavelength, absorption coefficient is quite low, and water absorption is still weak. This study has been supported by Monte Carlo simulations of light transportation in brain tissue. 129 The optical absorption and scattering coefficients of human breast tissues are identified for wavelengths from 500 to 1100 nm. It is found that the absorption coefficients are high at below 600 nm due to blood. The scattering coefficients lie in the range from 30 to 90 mm −1 at 500 nm and fall smoothly with increasing wavelength between 10 and 50 mm −1 at 1100 nm. 130 For skin and other tissues, the scattering coefficient decreases with an increase in wavelength, as shown in Fig. 1(b) . 127, [131] [132] [133] [134] [135] All these simulations and experimental studies have proved that wavelengths in the NIR-II region are more suitable for biomedical imaging.
For in vivo PAI, the maximum permissible pulse energy and the maximum permissible pulse repetition rate are governed by the ANSI laser safety standards. 101 The safety limits for the skin depend on the optical wavelength, pulse duration, exposure duration, and exposure aperture. For exposure time 10 to 3 × 10 4 s and spectral range from 0.4 to 1.4 μm, according to ANSI safety limit, the MPE ¼ 0.2C A W∕cm 2 , where, C A ¼ 1.0 (for 0.4 to 0.7 μm); 10 2ðλ−0.7Þ (for 0.7 to 1.05 μm); and 5.0 (for 1.05 to 1.4 μm). Similarly, for the exposure time 10 to 3 × 10 4 s and spectral range from 1.4 to 1.8 μm, the MPE ¼ 0.1 W∕cm 2 . For the spectral range from 0.4 to 1.8 μm, MPE as a function of wavelength is shown in Fig. 1(c) . This graph shows that the NIR-II window allows five times higher MPE for deep-tissue imaging compared to visible windows.
Implementing NIR-II PAI is comparatively straightforward. In conventional PAT systems, the excitation source is a pump laser (typically Q-switched 1064/532 nm Nd:YAG laser) and a second-stage OPO tunable in the range from 670 to 970 nm. For NIR-I PAI, 670 to 970 nm is used. OPO laser typically have 12% to 15% efficiency of generating light in the NIR-I range. For example: if a Nd:YAG pump laser produces 8 W of laser energy at 1064 nm, when it is converted to 532 nm, we get roughly 50% to 60% efficiency, i.e., ∼4-W energy. Further, when the 532-nm light is converted to NIR-I laser, we get around 100-to 130-mW energy. For NIR-II imaging, the powerful laser output from 1064 nm Nd:YAG laser can be used. The idler wavelengths of OPO tunable in the range from 1200 to 2000 nm can also be used for NIR-II imaging, but they have very low energy. Thus, the availability of high-power 1064-nm Nd:YAG laser has helped researchers to quickly start investigation on NIR-II window. However, a high-power laser tunable in the NIR-II window is still needed to fully utilize the benefits offered by this window. Thus, the reduced blood absorption, reduced scattering coefficients, high MPE offered by NIR-II window, and availability of high-power 1064-nm Nd:YAG nanosecond laser have motivated researchers to investigate its usefulness in PAI.
In Vitro Imaging
Biological tissues are generally opaque because photons traveling in the tissues are predominantly scattered rather than absorbed. Deep-tissue imaging becomes necessary to examine blood vessels, different organs (brain, kidney, liver, heart, etc.), and lesions/ tumors for preclinical/clinical applications. Scattering, absorption, and hence the imaging depth are strongly influenced by the excitation wavelength. Owing to the reduced scattering at NIR-II wavelengths, longer penetrations can be achieved. In this section, we discuss the deep-tissue imaging applications of PAT system operated at 1064 nm.
Deep-Tissue Imaging
PAT offers high depth-to-resolution ratio compared to pure optical imaging methods. An imaging depth of ∼5 cm is achieved in chicken breast tissue at 1064 nm. 136 A semiconducting polymer [named as poly (thienoisoindigo-alt-diketopyrrolopyrrole)-PIGD] is the contrast agent. Figure 2(a) shows the schematic representation of the PIGD nanoparticle. These particles are spherical, with an average diameter of 21 AE 5 nm. This dispersion results in a broad spectrum covering the range from 800 to 1200 nm with a maximum at 960 nm, as shown in Fig. 2(b) . The homemade PAT system used for deep-tissue imaging is shown in Fig. 2(c) . The excitation source is Nd:YAG laser (1064 nm, 5 ns, 10 Hz) from Continuum, Surelite Ex. The 1064-nm beam is expanded and homogenized using an optical ground glass to illuminate the sample. The sample and the ultrasonic transducer (UST) are immersed in water for coupling the PA signal to the transducer. A nonfocused transducer (V323-SU/2.25 MHz, 0.5 inch, Olympus NDT) is used for collecting the signals. The signals are subsequently amplified, bandpass-filtered by an US pulser/receiver unit (AU), (Olympus NDT, 5072PR) and then digitized and recorded by the PC with a data acquisition (DAQ) card (25 Ms/s, GaGe, compuscope 4227). For the cross-sectional imaging, the transducer is driven by a computer-controlled stepper motor to continuously move in a circular motion. The acquired A-lines are used for reconstructing the image using a delay-and-sum backprojection algorithm. The solutions of PIGD Nanoparticles (NPs) with three different concentrations (1.0, 0.5, and 0.25 mg/mL) are embedded in an agar gel phantom. The phantom is placed under chicken breast tissues with different thicknesses. Images of the phantom at different depths are shown in Figs. 2(d)-2(f). All three spots are detectable at the tissue depth of up to 5 cm [ Fig. 2(f) ]. The 1064-nm energy used on the tissue surface is ∼25 mJ∕cm 2 (less than the ANSI limit of ∼100 mJ∕cm 2 ). The 5-cm imaging depth promises that PIGD NPs could act as a potential agent for noninvasive deep-tissue imaging.
A linear-array-based PAT demonstrated an in vitro ∼12-cm imaging in chicken tissue using phosphorus phthalocyanine (P-Pc) as contrast agent. 37 P-Pc showed strong absorption around 1000 nm, as shown in Fig. 2(g) . The imaging system includes 1064 nm Nd:YAG excitation laser and a 128-element linear transducer array (5 MHz, ATL/Philips L7-4) for collecting PA signals. A Tygon tube (35-mm length, 5-mm inner diameter) containing 30 mM of P-Pc was placed in a 2-L glass beaker whose bottom was covered with 2.5-cm-thick chicken breast tissue [ Fig. 2(h) ]. To prevent leakage, both ends of the tube were sealed with epoxy glue. Figure 2(i) shows the PA/US image obtained after averaging 100 images acquired at the same depth of 11.6 cm. The image signal-to-noise ratio (SNR) was 18 dB and the energy on the tissue was ∼56 mJ∕cm 2 (still less than the ANSI safety limit). The deeper penetration was mainly attributed to the high absorption of P-Pc, weak tissue absorption and scattering, and the higher ANSI safety limit at 1064 nm. The 11.6-cm imaging depth achieved with 30 mM P-Pc at 1064 nm was significantly higher than the 8.4-cm depth achieved with 30 mM methylene blue at 650 nm. 137 Although these experiments were performed in chicken tissues, the deep detection of NIR-II nanoparticles through 5-to 12-cm-thick biological tissue showed its potential for preclinical applications that require whole-body penetration in small animals. 
Liver Imaging
Liver is the largest internal organ in the human body. After lymph nodes, liver is the second most common site of metastasis for cancers, such as pancreas, breast, colon, and stomach. Therefore, it is important to screen the formation of metastatic lesions in patients with cancer history. US, x-ray CT, PET, and MRI have been used for imaging liver lesions. Recently, the feasibility of PAT for imaging liver lesions ex vivo has been demonstrated at 1064 nm using gold nanorods. 124 The PAI contrast mostly depends on optical absorption of blood as compared to the background tissue. It is challenging to image liver lesions with PAT, because at any given time liver contains ∼10% of total blood in the body and it filters ∼1.4 L of blood per minute in adults. Owing to the strong absorption of blood, imaging liver is easy but imaging liver lesion/tumor with good contrast is inherently difficult for PAT operated in visible or NIR-I region. Liver phantom images are compared at 780 nm (NIR-I) and 1064 nm (NIR-II) in Figs. 3(a) and 3(b), respectively. The liver tissue generates a strong PA signal at 780 nm (due to the strong absorption of hemoglobin) compared to 1064 nm. By using 1064-nm excitation and strong 1064-nm absorbing agent, liver lesions imaging with high contrast is possible.
Gold (Au) nanorods resonant at 1064 nm are used as contrast agent for liver imaging. The absorption spectrum of PEGylated Au nanorods is shown in Fig. 3 (c); inset shows transmission electron microscopic (TEM) image of the nanorods. Figure 3(d) shows the schematic illustration of the liver phantom. Figure 3 (e) shows a series of PA/US images obtained at 1064 nm. The Au nanorod concentrations used in the inclusion are 5, 12.5, and 25 μg∕mL, respectively. An increased PA response from these inclusions has proved that plasmonic gold nanorods absorbing at 1064 nm can serve as a PA agent for liver imaging. The contrast of the images can be attributed to a combined effect from the suppression of background signal (due to the reduced blood absorption at 1064 nm) and the strong absorption of 1064-nm wavelength by the plasmatic gold nanorods. Although the in vitro studies are promising, lot more work is needed to study the feasibility of this approach for in vivo animals before going into clinical trials.
Brachytherapy
Brachytherapy is a form of radiation therapy commonly used in the treatment of prostate cancer. It involves implantation of small radioactive seeds around the treatment area. Currently, US imaging is used for seed implantation, but the seeds are difficult to distinguish from the tissue structure due to artifacts. Combined photoacoustic + US system operated at 1064 nm (NIR-II) is demonstrated for identifying brachytherapy seeds (BTSs) implanted at 5-cm deep inside the tissue phantom. In these images, seed-to-blood contrast-to-noise ratios are 15 and −0.5 dB, respectively. In the US image [ Fig. 4(e) ], the BTSs and the blood-filled tube are indistinguishable. But the overlaid PA signal correctly identifies the seed [ Fig. 4(f) ]. At 1064 nm, the blood-filled tube is indistinguishable from the background noise, whereas the BTSs are clearly visible. It should be noted that in this study the MPEs 20 mJ∕cm 2 at 760 and 797 nm and 100 mJ∕cm 2 at 1064 nm are used. The study showed that, by using 100 mJ∕cm 2 at 1064 nm, the BTSs at 5-cm-depth inside the chicken tissue are detected. It is a proof-of-concept study, but more rigorous in vivo animals and clinical studies should be undertaken.
In Vivo Small Animal Imaging
Small animals (especially rats, mice, etc.) are suitable models for preclinical studies, and they play an important role in studying human diseases and their effective treatments. 139 Standard preclinical imaging methods include MRI, x-ray CT, PET, UST, and optical methods (fluorescence, DOT, etc.). As an alternative to these modalities, PAT has emerged as a preclinical tool. Initially, visible window 140, 141 and later NIR-I window [141] [142] [143] [144] [145] had been used for in vivo animal imaging. In this section, we discuss the advanced PAT systems operated in NIR-II window for preclinical studies.
Whole-Body Imaging
Whole-body imaging of mouse was performed in visible and NIR-I windows. [146] [147] [148] Recently, using hemoglobin contrast, different organs (brain, heart, liver, and kidneys) of mouse were imaged using PAT at 1064 nm. 149 The imaging system used a compact high-energy 1064-nm diode-pumped Nd:YAG laser [ Fig. 5(a) ] with the following specifications: 3.2 ðLÞ × 14.0 ðWÞ × 6.5 ðHÞ cm, weight ∼1.6 kg, M 2 -factor (beam quality factor) ∼3, pulse energy ∼80 mJ, and pulse repetition rate 1 to 50 Hz, from Montfort Laser GmbH, Austria. The schematic representation of the PAT design used for trunk imaging is shown in Fig. 5(b) . For brain imaging, 1064-nm light with ∼12 mJ∕cm 2 energy was delivered to the scalp through a ∼1.2-cm diameter fiber bundle. Because the cortex is ∼1 mm beneath the scalp surface, top illumination was used. For trunk imaging, the light delivery was provided by a 6-cm-diameter ring fiber illuminator (Fiberoptic Specialties Light Source Flex Cable 12-Light RingMount). Along the ring, 12 circular fiber outputs (0.3 cm in diameter) were evenly distributed and were illuminating toward the ring center at a 60-deg angle (along the elevation direction). The PA signals were detected by a 270-deg ring transducer array (128 elements, 5 MHz, 40-mm ring diameter, 35-mm elevation focus). Brain, liver, and kidney regions were imaged with 10-Hz pulse repetition frequency over 50 s, whereas the heart region was imaged with 50 Hz pulse repetition frequency over 10 s. The tomography of mouse brain vasculature and liver has been shown in Figs. 5(c) and 5(d), respectively. These results clearly showed the high-speed imaging capacity of the 1064-nm PAT system. An advanced preclinical system, called the single-impulse panoramic PACT (SIP-PACT), was reported for the in vivo whole-body imaging of small animals at 1064 nm. 150 For whole-body imaging, a 1064-nm laser beam (50 Hz, 5 to 9 ns, DLS9050, Continuum) was expanded by an engineered diffuser (EDC10-A-1r, RPC Photonics) and then was passed through a conical lens (AX-FS-1-140-0, Del Mar Photonics) to form a ring-shaped beam which was refocused by an optical condenser. The 1064-nm light with ∼18 mJ∕cm 2 energy formed a ring pattern on the trunk of the mouse. For a two-dimensional (2-D) panoramic detection, a 512-element full-ring transducer (Imasonic Inc., 50-mm ring radius, 5 MHz, >90% one-way bandwidth) was used. Images were formed by a half-time dualspeed-of-sound universal backprojection algorithm. 151 The schematic representation of the system used for trunk imaging is shown in Figs. 5(e) and 5(f). The anatomy of different organs (brain, heart, lungs, liver, spleen, kidney, caecum, intestine, etc.) of the mouse was obtained with hemoglobin contrast. whole body of the mouse having a trunk width of ∼28 mm was clearly imaged with a spatial resolution of 125 μm and an imaging frame rate of 50 Hz. Thus, the NIR-II (1064 nm) excitation combined with advanced data acquisition and processing tools enabled SIP-PACT to complement other small-animal whole-body anatomical imaging modalities.
Brain Imaging
In vivo brain imaging was demonstrated in NIR-I and NIR-II windows using semiconducting polymer nanoparticles (SPNs). The details of the SPN-I having absorption in NIR-I, and SNP-II having absorption from visible to NIR-II regions can be found in Ref. 152 . The schematic representation of SPN-II nanoparticle and optical absorption spectra of SPN-I and SPN-II are shown in Figs. 6(a) and 6(b) , respectively. The SPN-II showed a spectrum ranging from visible to NIR-II region with the maximum peak at 1253 nm. The SPN-II (6 mg/mL, 300 μL per rat) was injected into the rat through intravenous injection. After injection, brain images were acquired using the homemade PAT system, as shown in Fig. 6(c) . Postinjection brain images were acquired at 750 nm for up to 70 min. It was observed that the PA signals from the blood vessels increased by 66% and the SNR was enhanced by about 1.5-fold after injection. The SNR was stabilized for 70 min, indicating the long circulation of SPN-II in blood owing to its small diameter (∼54 nm) and PEG-passivated In vivo whole-body imaging of the mouse using SIP-PACT system: (e) schematic representation of the system used for trunk imaging; (f) close up of the green dashed box region in Fig. 4(e) , which shows the confocal design of light delivery and photoacoustic detection. BC, beam combiner; CL, conical lens; MBS, magnetic base scanner; OC, optical condenser; USTA, full-ring ultrasonic transducer array; WT, water tank. Label-free SIP-PACT of the mouse wholebody anatomy from the brain to the trunk: (g) vasculature of the brain cortex, cross-sectional images of the (h) upper thoracic cavity, (i) lower thoracic cavity, (j) two lobes of the liver, (k) upper abdominal cavity, and (l) lower abdominal cavity. IN, intestines; LL, left lung; LV, liver; RK, right kidney; SC, spinal cord; SP, spleen; SV, splenic vein; TA, thoracic aorta; and VE, vertebra. Reproduced with permission from Ref. 150. surface. For comparison, brain images were shown at both 750 [ Fig. 6(d) ] and 1064 nm [ Fig. 6(e) ]. The SNR at 1064 nm (27.7 AE 4.1 dB) was 1.5-fold enhanced than that at 750 nm (18.2 AE 4.9 dB). These results confirmed the advantage of NIR-II over NIR-I PAI.
The PIGD nanoparticles (discussed in Sec. 3.1) were also demonstrated for in vivo brain imaging at 1064 nm. 136 The cerebral cortex of a rat brain was imaged at 1064 nm before and after a single injection of PIGD NPs (0.25 mL per rat, 2 mg/mL). The cross-sectional images of the rat brain at 0 min (before injection) and 70 min after injection are shown in Figs. 6(f) and 6(g), respectively. The PA signal and image SNR as a function of postinjection time are shown in Fig. 6(h) . The SNR of the image acquired at 0 min was ∼18 dB and it increased to ∼37 dB at 70 min, i.e., an approximately twofold enhancement at 70-min postinjection. After 70 min, the PA signal remained strong, indicating that a sufficient amount of NPs circulate in the blood. Long circulation of NPs could be due to their suitable size of ∼25 nm and the PEGylated surfaces. This in vivo brain imaging proved that even though blood absorption is low in the NIR-II window, by using suitable long-circulating nanoparticles, it is possible to achieve contrast-enhanced PAI of brain vessels of small animals with intact skin and skull. Several rat/mouse brain imaging works at 1064 nm using agents can be found in Refs. 154 and 155. Without the contrast agent, the cross section of a relatively large animal (monkey) brain cortex with skull thickness of ∼2 mm was imaged at 1064 nm with energy density 50 mJ∕cm 2 .
156 With a strong 1064-nm agent, PAT can potentially image through even thicker skull bones. These results suggest that the NIR-II PAT system can potentially image human brain cortex in infants or even adults; however, more studies are needed in this direction.
Interestingly, a wearable scanning PAI (wPAI) system capable of detecting HbO, HbR, and HbT changes within the rat brain vasculatures under hyperoxia by using 1064, 710, and 797 nm wavelengths was reported. 157 Later a 1064-nm wPAI was demonstrated for dorsoventral brain images noninvasively in behaving rats. 153 Figure 6(i) shows the photograph of a 1064-nm wPAI probe. The 1064-nm beam was weakly converged and overlapped with the acoustic detection of a 40-MHz microtransducer, which was attached to a cantilever. Figures 6(j) and 6(k) present wPAI images at positions of Bregma −7.3 mm and Bregma −2 mm. The PA images provided brain vasculature information beneath the skull. The system could provide ∼0.5-mm lateral and 0.1-mm axial resolutions, and 11-mm imaging depth with 1064-nm light and 40-MHz UST. The findings suggested that wearable PAT (wPAT) can be used for studying pathological events such as stroke, brain ischemia, and seizure.
Lymph Nodes Imaging on Rats
Sentinel lymph node (SLN) mapping is an important task for the staging of breast cancer, especially to find out if metastasis has happened or not. PAT is widely used for SLN imaging. 64, 67, 158 In vivo lymph node imaging at 1064 nm is performed on rats using copper sulfide (CuS). 123 A single-element UST-scanning PAT system, as described in Ref. 145 , is used for the SLN imaging. It includes a Nd:YAG laser (1064 nm at 1000 mJ, 15 ns, 10 Hz, model: LS-2137) from Symphotic Tii, Camarillo, and an unfocused UST (V323/2.25 MHz, Panametrics). The incident laser energy density is kept below ∼100 mJ∕cm 2 . The signals are subsequently amplified by amplifiers (ZFL-500LN, MiniCircuits and 5072PR, Panametrics), bandpass filtered, and finally recorded using a DAQ card (CS14100, Gage Applied, Inc.).
A semiconductor CuS nanoparticles with absorption around 1064 nm is demonstrated for enhancing the SLN contrast in living mouse. After interstitial injection of CuS NPs, the rat lymph nodes of ∼12 mm below the skin are clearly visible. Figure 7 shows the PAT images of the axillary and brachial lymph nodes of a rat 24 h after interstitial injection of CuS NPs into the front paw pad. The lymph nodes, located 12 mm below the skin surface, are clearly visualized [ Fig. 7(a) ], the corresponding photograph is shown in Fig. 7(b) . In contrast, the axillary and brachial lymph nodes on the contralateral side, which did not receive an interstitial injection of CuS NP, are not visualized on PAT [ Fig. 7(c) , its photograph is in Fig. 7(d) . To ensure that the lymph nodes are within the imaging field of view, stainless steel needle tips are placed adjacent to the targets as a reference [red arrows on Figs. 7(c) and 7(d)]. PAT images in all rats depict the uptake of CuS NPs by ipsilateral draining lymph nodes. A representative lymph node image and its one-dimensional PA signal profile are shown in Figs. 7(e) and 7(f), respectively. The PA signal intensity is significantly higher in lymph nodes containing CuS NPs (7.85 AE 3.78) than in lymph nodes without CuS NPs (2.46 AE 0.73). TEM image of CuS NPs (average size ∼11 nm) and the extinction coefficient spectrum (peaked around 990 nm) of 0.5 mM CuS are shown in Figs. 7(g) and 7(h), respectively. The imaging of the lymph node located at ∼12-mm depth in a living rat promises that NIR-II PAT in combination with 1064-nm absorbing CuS nanoparticles could potentially be used for in vivo lymph node imaging in humans; however, clinical studies are needed to establish this.
Canine Prostate Imaging
Real-time visualization of regions of interest during surgery and biopsy procedures is important for clinicians. Clinically established modalities, such as MRI, PET, and CT allow whole-body scans and are ideal for diagnostic purposes. Owing to their very low-imaging speed, they are not suitable for real-time applications. Currently, US imaging is used for image-guided treatments. However, it is often difficult to deliver miniature probes to the surgical site without sacrificing the image quality. PAI has the potential to enable real-time visualization of regions of interest during surgery [159] [160] [161] [162] and biopsy. 163, 164 A 1064-nm side-firing fiber prototype for transurethral PAI of prostates with a dual-array (4-8 MHz/linear and 5-9 MHz/curvilinear) is reported. 165 The design and photograph of the 1064-nm sidefiring fiber are shown in Figs. 8(a) and 8(b) , respectively. The CT image of a BTS implanted in the canine prostate is shown in Fig. 8(c) . The seed is implanted in the apex of the prostate and is imaged with US, as shown in Fig. 8(d) ; the arrow points to the BTS. The corresponding PA image [ Fig. 8(e) ], overlaid on the US image, contains the seed and the signals in the urethra and associated reverberation artifacts (likely caused by the metal tip). These artifacts are eliminated in Fig. 8(f) . Thus, the BTS implanted in in vivo canine prostates at radial distances of 5 to 30 mm from the urethra are imaged with the fiber prototype transmitting 1064-nm wavelength light with 2-to 8-mJ pulse energy. It can display images in real time at a rate of 3 to 5 frames per second to guide fiber placement and beamformed offline.
Skin and Tumor Imaging
PAI of skin was performed in the visible region. [166] [167] [168] Recently, skin and tumor imaging on small animals was demonstrated using the thienoisoindigo-based semiconducting polymer nanoparticles (TSPNs) [ Fig. 9(a) ]. It has strong absorption in 800 to 1350 nm [ Fig. 9(b) ] for PAI in the NIR-II window. 169 An US imaging system (Vantage128, Verasonics Inc.) with EKSPLA OPO laser (5 ns and 10 Hz) was used for imaging. A refection-mode detection was applied using a high-frequency US array (L22-14v, Verasonics Inc.). For skin imaging [ Fig. 9(c) ], TSPNs (50 μL, 40 μg∕mL) were injected subcutaneously into the dorsal area of the rats. Without injection, the PA signal was weak at 1100 and 1300 nm and strong at 800 and 1000 nm, due to the absorption of blood at these wavelengths. The strong signal at 1200 nm was generated from the subcutaneous fat in the skin layer. After injection, the PA signal increased by ∼7.3-fold at 1100 nm and by ∼10.7-fold at 1300 nm, compared to the signal found in the skin tissue without injection. This significant signal enhancement indicated the capability of TSPN as an exogenous contrast agent for in vivo skin imaging.
In vivo images of tumor in mice with and without TSPNs are shown in Fig. 9(d) . TSPNs are directly injected into PC3-M xenografts in mice. Without TSPNs, relatively strong PA signals are observed from the tumor at 800 and 1000 nm, which are attributed to the rich blood vessels surrounding the tumor. The signals above the tumor at 1200 nm are more likely from skin fats. Intratumoral injection was performed to deliver TSPNs (50 μL, 40 μg∕mL) into the tumor area, then strong PA signals were generated within the tumor area (dashed circles) due to the strong absorption of excitation wavelengths 800 to 1300 nm by the TSPNs. Compared to the images of the tumor without TSPNs, the signal was enhanced ∼7.0-fold at 1100 nm and ∼13.3-fold at 1300 nm. Reports on NIR-II tumor imaging 116, 154 promised that it can provide high sensitivity and depth for tumor imaging compared to NIR-I window.
Urinary Bladder Imaging
Urinary bladder imaging is critical to diagnose urinary tract disorders and bladder cancer. Recently, bladder imaging in rats has been shown with clinical US + PAI system. 63 A clinical research US system (E-CUBE 12R, Alpinion, South Korea) that can acquire PA and US images simultaneously is used.
A linear array transducer (L3-12, 8.5 MHz, 95% fractional bandwidth) with 128 elements is used for data acquisition. For PAI, 1064-nm light from a Nd:YAG pump laser (10 Hz, 5 ns, Continuum, Surelite Ex) is transmitted through the bifurcated optical fiber bundle (Ceramoptec GmbH, Germany). The two rectangular fiber bundle output are fixed to the linear array transducer in such a manner that the fiber-to-transducer distance is ∼2 cm, the fiber-to-tissue distance is ∼1 cm, and a light delivery angle is at 15 deg. The energy on the rat skin is kept at ∼9 mJ∕cm 2 . Using this system, the structural (bladder wall), functional (accretion of gold nanoparticles), and the diagnosis of vesicoureteral reflux, a common bladder disorder, are successfully demonstrated in NIR-II window.
Lipid Profile Imaging
Lipid-based conditions appear in many diseases that include diabetes, obesity, fatty liver disease, and vascular diseases, such as coronary artery disease and peripheral artery disease. Optimum wavelengths for nerve or lipid imaging are 910, 1210, and and with injection of 50 μL, 40 μg∕mL aqueous solution of TSPNs (lower). The laser energy density is ∼10 mJ∕cm 2 at 800 nm, 19 mJ∕cm 2 at 1000 nm, 33 mJ∕cm 2 at 1100 nm, 37 mJ∕cm 2 at 1200 nm, and 25 mJ∕cm 2 at 1300 nm. Each image is normalized with the corresponding laser energy density. Reproduced with permission from Ref. 169. 1700 nm. 170, 171 Recently, in vivo murine lipid imaging is shown at 1210 nm on mice of different gender, genotypes, and maturation. 172 The system used is an US system (Vevo2100, FUJIFILM Visual Sonics) equipped with a high-frequency transducer (MS550D, 40 MHz) to obtain PA + US images of the infrarenal aorta. A Nd:YAG/OPO laser (NT352C, Ekspla, 670 to 2300 nm, 5 ns, 10 Hz) is used for lipid imaging. The US images of infrarenal aorta of apolipoprotein E-deficient (apoE−/−) and wild-type (WT) mice are shown in Figs. 10(a) and 10(d), respectively. The system resolves subcutaneous and periaortic fat buildup in both mice. The lipid-specific PAT signal follows both the geometry of the skin due to the subcutaneous fat and the infrarenal aorta due to periaortic fat accumulation. The adult male apoE−/− mice show more fat accumulation compared to the adult male WT mice. The raw [Figs. 10(g) and 10(h)] and averaged [ Fig. 10(i) ] PAT images at 1210 nm reveal subcutaneous and periaortic fat. In vivo lipid PAI is also reported at 1197 nm. 170 The light used for these studies is the low-energy idler light from OPO lasers. So, there is a need for high-pulse energy (hundreds of mJ) laser with a lipidspecific wavelength of 910, 1210, 1700 nm and with a pulse repetition rate of at least 10-kHz level for high-speed imaging.
In Vivo Human Imaging
In vivo human imaging is the ultimate goal. However, it is challenging. Whole-body MRI, x-ray CT, scintigraphy, PET CT scan, etc. are being used in clinics. The above-discussed deep-tissue and in vivo animal-imaging studies show promise that PAT has matured over the years and is progressing toward clinical use. This section discusses the advanced PAT systems operated at 1064 nm and their successful applications on humans for diagnosis purposes.
Human Breast Imaging
Breast cancer is the most common cancer among women. Symptoms include a lump or thickening of the breast and changes to the skin or the nipple. For breast cancer screening, mammography is still the gold standard. In recent times, MRI or even ultrasonography is being used as an alternative. Even the optical imaging modality, DOT, is used for monitoring neoadjuvant chemotherapy in patients with breast cancer. PACT has emerged as an alternative tool that overcomes many of the limitations associated with the existing modalities. [173] [174] [175] A Twente photoacoustic mammoscope (Twente PAMa) based on a 1064-nm laser was developed [ Fig. 11(a) ] for human breast imaging. 177, 176 The PAMa included a Nd:YAG laser (1064 nm, 10 ns, 10 Hz, 350 mJ) from Continuum Surelite and an US array consisting of 588 elements (1 MHz) in a circular layout with a diameter of 85 mm. The 1064-nm beam was maintained at a fixed position on the breast surface, with a beam area of ∼35 cm 2 and an energy density of ∼10 mJ∕cm 2 on the breast skin. An imaging time of 10 min was required for the complete detector area covering a field of view of 90 × 85 mm 2 on the breast. Figures 11(b) and 11(c) show the images in craniocaudal direction of MRI and PAT. The results showed that there is a good correspondence in lesion colocalization, appearance, and shape in the PAT and MRI images. The study has proven that PAI has potential in visualization of breast cancer. For the first time, mass-like, nonmass, and ring appearances were observed in PA images. A photoacoustic mammography system that can provide several wavelengths, such as 756, 797, 825, and 1064 nm (Canon Inc., Tokyo, Japan), was demonstrated for tumor morphology. 178, 179 Very recently, a single-breath-hold photoacoustic computed tomography (SBH-PACT) system, as shown in Fig. 11(d) , was demonstrated for volumetric imaging of the human breast. 36 The system used a 1064-nm light to achieve sufficient optical penetration in the breast tissue. The 1064-nm laser beam (PRO350-10, Quanta-Ray, 10 Hz, 8 to 12 ns) was first passed through an axicon lens (25 mm, 160-deg apex angle), and was then expanded by an engineered diffuser (EDC-10-A-2 s, RPC Photonics) to form a donut-shaped light beam. The 1064-nm laser energy on the breast was ∼20 mJ∕cm 2 . To achieve a 2-D panoramic acoustic detection, a 512-element full-ring UST array (Imasonic, Inc., 220-mm ring diameter, 2.25 MHz) was employed. Four sets of 128-channel data acquisition systems provided simultaneous one-to-one mapped associations with the 512-element transducer array. A 128-channel data acquisition system (SonixDAQ, Ultrasonix Medical ULC, 40 MHz, 12 bit) with programmable amplification up to 51 dB was used. Therefore, time taken to acquire PA signals from a cross section was within 100 μs without multiplexing after each laser pulse excitation.
The performance of SBH-PACT was assessed by imaging a 27-year-old healthy female volunteer. By scanning the transducer array elevationally through her right breast, within one breath-hold (∼15 s), a volumetric image was acquired. The angiographic anatomy from the nipple to the chest wall was revealed. The breast images at different depth are shown in Figs. 11(e)-11(h) . The color-encoded depth-resolved image clearly revealed the detailed angiographic structures of the entire breast [ Fig. 11(i) ], visualizing the vasculature down to an apparent vascular diameter of 258 μm. The system could provide a depth of ∼4 cm, a spatial resolution at ∼255 μm, and a frame rate of ∼10 Hz. Using hemoglobin as the contrast, SBH-PACT can potentially monitor breast cancer's response to neoadjuvant chemotherapy by acquiring information similar to that of contrast-enhanced MRI, yet with finer spatial resolution, higher imaging speed, and only endogenous contrast.
Human Arm Imaging
The second window is demonstrated for PAI of deep vasculature in human hand and palm. The system design used for arm/palm imaging is shown in Fig. 12(a) . 149 The system uses a compact 1064-nm laser (described in Sec. 4.2) and a bifurcated fiber bundle with circular input (1-cm diameter) and two line outputs (5-cm length) to deliver light to the arm/palm. The 1064-nm energy density used on the 5-× 1-cm skin surface is 8 mJ∕cm 2 at 50 Hz. For PA signal detection, an ATL/Philips L7-4 liner transducer array (elevation focus 25 mm and resolution 1.5 mm) is used. During data acquisition, the object is kept stationary, and the transducer and fiber bundles scanned over a 75-mm region at a speed of 1 mm/s. The system could scan 40- . As expected, vascular distribution in the arm is much thinner than that of the palm. The SNR of the images is calculated using the selected signals (box 1 and box 3) and noises (box 2 and box 4). The SNR of the arm image is 39 dB and that of palm image is 36 dB; no endogenous contrast agent has been used in this study.
Another 1064-nm PA/US system, as shown in Fig. 12(f) , was demonstrated imaging through a human arm with highly absorbing contrast agent (P-Pc) at 1064 nm. 37 A tube containing the P-Pc formulation was placed beneath the arm of a healthy and conscious human adult. The arm was first imaged without the tube; the US could visualize the whole arm and no PA signal was present [ Fig. 12(g) ]. The US signal visible at the bottom of the arm corresponded to the US reflection from the supporting agar gel under the arm. However, when a tube containing P-Pc was placed under the arm, its complete shape could be visualized through the 3.1-cm arm with an energy density of ∼14 mJ∕cm 2 [ Fig. 12(h) ]. For another volunteer with a larger arm, the fluence used was 23 mJ∕cm 2 . The P-Pc tube was clearly detectable through the 5-cm arm [Figs. 12(i)-12(j)]. There was no bone visible in the imaging plane, because the transducer imaged in the gap between the ulna and the radius bones. Skin was not easily observed in the images because the transducer was placed directly on it.
6 High-Resolution Photoacoustic Imaging in Near-Infrared-II Window
Till now we have discussed the second window PAT/PACT systems and their deep-tissue (several centimeters) applications for live animal and human organ imaging. The usefulness of the second window is also demonstrated in high-resolution PAM imaging system. Typically in PAM the imaging depth is sacrificed to achieve higher resolution. For example, in optical resolution photoacoustic microscopy (OR-PAM), typical imaging depth up to 1 to 2 mm is obtained with lateral resolution of 0.25 to 5 micron, 180, 181 and in acoustic resolution microscopy (AR-PAM), 3 to 8 mm imaging depth is obtained with lateral resolution of 40 to 50 micron. 182, 183 Most of the PAM systems reported so far have used visible or NIR-I window due to the strong hemoglobin absorption. Recently, OR-PAM was reported for the first time in the second NIR window. 113 The system includes a Nd:YLF/dye-laser (1046, 523, and 570 nm) and a 50-MHz UST. The OR-PAM images of a 50-μm-diameter black human hair obliquely inserted into a piece of fresh chicken breast tissue at 570 nm (visible), and 1046 nm (NIR-II) are shown in Figs. 13(a) and 13(b), respectively. The energy densities on the tissue surface at 570 and 1046 nm are 20 and 100 mJ∕cm 2 , respectively. A 1046-nm wavelength could image a 3.2-mm thick hair beneath the skin surface with a SNR of 6 dB, whereas a 570-nm wavelength could image only up to 2.3-mm depth with the same SNR. Similarly, the same area of the mouse brain is imaged at 570 [ Fig. 13(c) ] and 1046 nm [ Fig. 13(d) ]. At 570 nm, blood vessels are clearly visible up to 0.25 mm and few vessels are visible up to 0.5 mm due to the strong blood absorption at 570 nm. On the other hand, the 1046-nm wavelength could show vessels up to 0.75 mm. The longer penetration and high spatial resolution in OR-PAM are due to the weaker optical attenuation and high ANSI limit of the NIR-II window.
Unlike OR-PAM, where tight optical focusing is used to achieve high resolution, in AR-PAM, lateral resolution is mainly dictated by the US focusing. As a result, imaging depth is increased to several millimeters with a compromised lateral resolution of 40 to 50 micron. All the AR-PAM systems reported so far use visible or NIR-I window. Very recently, a 1064-nm AR-PAM system has been reported for deep-tissue and in vivo imaging. 184, 185 A black tape embedded in a chicken breast tissue is imaged up to 11 mm, as shown in Fig. 13(e) . In vivo imaging of SLN [ Fig. 13(f) ] and urinary bladder [ Fig. 13(g) ] in rats using black ink as a contrast agent are reported. The system integrates a Nd:YAG (1064 nm) with 30-MHz focused UST. Before injection, lymph node and urinary bladder are hardly visible. The black ink enhances the SLN and UB contrast, as shown in Figs. 13(f) and 13(g), respectively. The energy per pulse used for in vivo imaging is 1 mJ∕cm 2 . Thus, using NIR-II wavelengths further enhances the depth and resolution capabilities of PAM. 
Summary and Perspectives
We have discussed the advanced PAT systems and contrast agents developed for NIR-II imaging. Numerous applications of the second window for in vitro studies, in vivo small animal imaging, and in vivo human imaging have been discussed. Imaging depth of up to ∼12 cm was demonstrated using P-Pc at 1064 nm at 56 mJ∕cm 2 . 37 Imaging of the liver lesions was performed at 1064 nm using gold nanorods. 124 Advantage of using the 1064-nm wavelength for brachytherapy has been shown by imaging a radioactive substance embedded 5-cm deep inside a tissue phantom. 138 In vivo skin imaging on rats was performed at 800, 1000, 1200, and 1300 nm, and lowest signal was observed at 1300 nm. 169 Although the above studies have used NIR-II agents, NIR-II window has shown its potential for PAI without an exogenous agent: in vivo small animal brain imaging and whole body of small animals using blood contrast at 1064 nm. 149, 150 In vivo human imaging at 1064 nm was successfully demonstrated by imaging human palm/arm, 149 and breast 36 without a contrast agent. The cross section of the monkey brain cortex with a skull thickness of ∼2 mm was imaged at 1064 nm with energy density of 50 mJ∕cm 2 . 156 The PAT images at 1210 nm revealed the lipid (subcutaneous fat, periaortic fat) profile along the anterior wall of the infrarenal aorta of mouse. 172 These studies have proved that NIR-II PAT system operated at 1064 nm is a very promising tool for preclinical applications. Twente PAMa is demonstrated for human breast imaging at 1064 nm with the energy density of 10 mJ∕cm 2 . The system could image the tumor inside the breast but cannot provide blood vessel information inside and around the tumor due to its poor resolution (∼3.5 mm). Imaging speed of this system is very low (10 min/image) and hence is not suitable for dynamic imaging. 176 The SBH-PACT, an advanced three-dimensional breast imaging system using 1064 nm, is a promising tool for both clinical screening and diagnostic studies. 36 It offers 4-cm depth (1064 nm at 20 mJ∕cm 2 ) to image the whole breast, 255-μm high resolution to reveal blood vessels in and around tumor, and 10-Hz high frame rate for dynamic imaging. No exogenous contrasts have been used in both Twente PAM and SBH-PACT for breast imaging. This proves the clinical potential of 1064 nm PACT for human imaging applications.
To compensate for the reduced blood (an intrinsic contrast agent) absorption in NIR-II region, several NIR-II absorbing agents were developed. Here, we have listed out some of the agents and the wavelength of maximum absorbance in the second window: (i) NIR-II inorganic contrast agents-singlewalled carbon nanotubes (1064 nm 126 ), CuS nanoparticles (990 nm 123 ), Ag nanoplates (1050 nm 125 ), Au nanorods (1040 nm 124 and 1064 nm 186 ), silica-coated gold nanoplates ), etc. Though they have broad spectrum, all these nanoparticles were demonstrated for PAI at 1064 nm due to the availability of high-energy pulsed laser at this wavelength.
Although these exciting studies have shown the potential of NIR-II window for preclinical and clinical PAI, the NIR-II imaging is still in its infancy. Like any other newly developed imaging technology, second window imaging also has some fundamental and technological challenges: (i) NIR-II contrast agents with excellent biocompatibility and favorable clearance profiles similar to those of the clinically approved NIR-I small molecule dyes (ICG, methylene blue, Evans blue) are needed; (ii) biocompatibility, pharmacokinetics, and long-term toxicity of NIR-II contrast agents is not sufficient; (iii) tunable yet powerful NIR-II pulsed laser is not available; (iv) optical properties of biological tissues required for fundamental studies need to be identified in the NIR-II region. The NIR-II contrast agent synthesis studies have focused on developing nanomaterials with low quantum yield (increasing the nonradiative transitions) to enhance their PA efficiency. But the major challenge revolves around the elucidation of the biocompatibility, pharmacokinetics, and long-term toxicological profile of the NIR-II agents, which are crucial for medical applications. 188 There is a potential leakage of heavy metal ions from inorganic NIR-II contrast agents. Some of the NIR-II organic nanoparticles, such as SPNs, have long circulation time; they stay several days in the body. For NIR-II imaging, there is no FDA-approved small molecule for clinical use. P-Pc is a small molecule that could readily be formulated in commonly used surfactants to produce solutions with extreme absorption beyond 1000 nm. The P-Pc is used for PAI through 11.6 cm of chicken breast tissue. Although this molecule is used in tissue phantoms, the deep detection of P-Pc through over 10 cm of biological tissue shows its potential for clinical applications. However, still more research work needs to be done to develop an ideal NIR-II PA contrast agent that shows fast and complete clearance from the body, high photothermal conversion efficiency, and low cost.
Another challenge is developing a tunable yet powerful NIR-II laser. Although the NIR-II contrast agents show broad absorption, they are demonstrated for PAI at 1064 nm due to the availability of 1064-nm high-energy pulsed lasers in laboratory/market. The applications of the single-wavelength PAT are limited to structural imaging. It is challenging to extract functional information with a single-wavelength excitation; usually two or more wavelengths are needed. 189 If the absorption peak of the contrast agent does not match with the excitation wavelength (e.g., 1064 nm), its real efficiency cannot be demonstrated. So there is an urgent need for developing a high-energy nanosecond laser tunable in the NIR-II window. The commercial Vevo LAZR-X multimodal PA/US system is incorporated with a laser source that can deliver 680 to 970 nm (NIR-I) and 1200 to 2000 nm (NIR-II). 190 However, nanosecond lasers that can provide energy density as high as 100 mJ∕cm 2 or even more are needed to fully utilize the high MPE of the second window. The idler wavelengths of commercial Nd:YAG/OPO laser fall in the NIR-II region, but their energy levels (which are very low compared to NIR-I window) and beam quality makes it not ideal for the second window imaging. Fundamental studies on light penetration in biological tissue at different wavelengths are still needed for quantitative image analysis. The large variations in the tissue composition across different organs and different individuals makes it difficult to carry out quantitative studies. The applications of NIR-II PAT are still at the early stage; most of them are proof-ofconcept studies, and so more complex imaging applications, including functional imaging, molecular imaging, 24 metabolism imaging, 191 biosensing, 192 and human disease [193] [194] [195] need to be demonstrated.
Conclusion
Overall, the above studies have proved that, compared to the NIR-I window, the NIR-II window offers longer penetration depth and high contrast imaging due to the (1) reduced tissue scattering, (2) minimal tissue absorption, (3) higher MPE offered by the NIR-II window, and (4) lower cost. Shifting the excitation window from NIR-I to NIR-II has significantly enhanced the performance of PAI systems by improving the depth and image quality. By employing fast scanning technologies, multiple wavelengths, miniaturized laser technology, efficient yet safe contrast agents, and by combining with existing modalities, PAT can become a promising tool for clinical screening, diagnosis, and therapy applications in the near future.
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